Bis-choline tetrathiomolybdate - Wilson Therapeutics

Drug Profile

Bis-choline tetrathiomolybdate - Wilson Therapeutics

Alternative Names: ATN-224; Decuprate; WTX-101

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Attenuon LLC
  • Developer Attenuon; Wilson Therapeutics
  • Class Antineoplastics; Heavy metals; Neuroprotectants; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatolenticular degeneration
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatolenticular degeneration
  • Discontinued Malignant melanoma; Multiple myeloma; Prostate cancer; Solid tumours

Most Recent Events

  • 05 Dec 2016 Adverse events and efficacy data from a phase II trial in Wilson's disease released by Wilson Therapeutics9208327
  • 05 Dec 2016 Wilson Therapeutics plans a phase III trial for Wilson's disease in 2017
  • 11 Nov 2016 Updated efficacy and safety data from phase II trial in Wilson's disease released by Wilson Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top